Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · July 25, 2018

Semaglutide vs Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise

Diabetes Care

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
Diabetes Care 2018 Jul 19;[EPub Ahead of Print], I Lingvay, CV Desouza, KS Lalic, L Rose, T Hansen, J Zacho, TR Pieber

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading